Stage IIIA Skin Melanoma Active Not Recruiting Phase 3 Trials for DB00105 (Interferon Alfa-2b, Recombinant)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02506153High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryTreatment